PE61899A1 - Composicion farmaceutica para reducir la hipertension ocular que comprende una prostaglandina y un agente de ajuste de tonicidad no ionico - Google Patents

Composicion farmaceutica para reducir la hipertension ocular que comprende una prostaglandina y un agente de ajuste de tonicidad no ionico

Info

Publication number
PE61899A1
PE61899A1 PE1998000177A PE00017798A PE61899A1 PE 61899 A1 PE61899 A1 PE 61899A1 PE 1998000177 A PE1998000177 A PE 1998000177A PE 00017798 A PE00017798 A PE 00017798A PE 61899 A1 PE61899 A1 PE 61899A1
Authority
PE
Peru
Prior art keywords
composition
mixtures
conservative
ionic
prostaglandine
Prior art date
Application number
PE1998000177A
Other languages
English (en)
Inventor
Kenneth Warren Reed
Shau-Fong Yen
Mary Sou
Regina Flinn Peacock
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE61899(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE61899A1 publication Critical patent/PE61899A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION OFTALMICA QUE COMPRENDE a)PROSTAGLANDINA , SUS METABOLITOS, DERIVADOS, SALES Y MEZCLAS; b) CONSERVADOR OFTALMICO, SELECCIONADO ENTRE SULFATO DE POLIMIXINA B, COMPUESTOS DE AMONIO CUATERNARIO; CONSERVADOR DEBIL COMO PEROXIDOS, GENERADORES DE PEROXIDOS Y SUS MEZCLAS; ENTRE OTROS c) UN AGENTE DE AJUSTE DE TONICIDAD NO IONICO PRESENTE EN UNA CONCENTRACION SUFICIENTE PARA i)AJUSTAR LA TONICIDAD DE LA COMPOSICION; ii)INCREMENTAR LA EFECTIVIDAD DEL CONSERVADOR, SELECCIONADO ENTRE MANITOL, SORBITOL, GLICEROL, ENTRE OTROS; d)UN VEHICULO OFTALMICAMENTE ACEPTABLE; COMPRENDE ADEMAS UN AGENTE DE QUELACION COMO EDTA O SU SAL; UN TENSOACTIVO NO IONICO SELECCIONADO DE ESTERES DE ACIDO GRASO DE SORBITAN DE POLIOXIETILENO, ETERES ALQUILICOS DE POLIOEXIETILENO, POLISORBATO 80 Y SUS MEZCLAS, ENTRE OTROS. EL AGENTE ACTIVO ES UN 13,14-DIHIDRO-15-CETO-20-ETIL-PROSTAGLANDINA F2O-ESTER ISOPROPILICO. TAMBIEN COMPRENDE UN REGULADOR DE pH COMO EDTA, BORATOS Y FOSFONATOS, QUE MANTIENE LA COMPOSICION EN UN pH DE 5,5 A 8,5 DURANTE UN ANO. UNA COMPOSICION PREFERIDA ES UN AGENTE ACTIVO DE PROSTAGLANDINA, UN PRIMER TENSOACTIVO NO IONICO COMO POLISORBATO Y UN SEGUNDO TENSOACTIVO NO IONICO COMO COMPUESTO BRIJ Y UN VEHICULO OFTALMICAMENTE ACEPTABLE. LA COMPOSICION PUEDE SER UTIL PARA LA HIPERTENSION OCULAR
PE1998000177A 1997-03-17 1998-03-13 Composicion farmaceutica para reducir la hipertension ocular que comprende una prostaglandina y un agente de ajuste de tonicidad no ionico PE61899A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81922197A 1997-03-17 1997-03-17

Publications (1)

Publication Number Publication Date
PE61899A1 true PE61899A1 (es) 1999-06-30

Family

ID=38729083

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000177A PE61899A1 (es) 1997-03-17 1998-03-13 Composicion farmaceutica para reducir la hipertension ocular que comprende una prostaglandina y un agente de ajuste de tonicidad no ionico

Country Status (33)

Country Link
EP (1) EP0969846B2 (es)
JP (2) JP4920124B2 (es)
KR (1) KR100555818B1 (es)
CN (1) CN1236775C (es)
AR (2) AR002194A1 (es)
AT (1) ATE257385T1 (es)
AU (1) AU738781B2 (es)
BR (2) BR9808016A (es)
CA (1) CA2280089C (es)
CL (1) CL2009001870A1 (es)
CO (1) CO4940427A1 (es)
CY (1) CY2526B1 (es)
CZ (1) CZ299833B6 (es)
DE (1) DE69820997T3 (es)
DK (1) DK0969846T4 (es)
EE (1) EE04091B1 (es)
ES (1) ES2214706T5 (es)
HK (1) HK1026841A1 (es)
HU (1) HU228896B1 (es)
ID (1) ID22389A (es)
IL (1) IL131041A0 (es)
MY (1) MY122237A (es)
NO (1) NO327713B1 (es)
NZ (1) NZ337322A (es)
PE (1) PE61899A1 (es)
PL (1) PL197509B1 (es)
PT (1) PT969846E (es)
RU (1) RU2197970C2 (es)
SI (1) SI0969846T2 (es)
TW (1) TW527187B (es)
UA (1) UA63938C2 (es)
WO (1) WO1998041208A1 (es)
ZA (1) ZA982188B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6187818B1 (en) * 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
TWI290470B (en) * 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
KR100854056B1 (ko) * 2000-09-13 2008-08-26 산텐 세이야꾸 가부시키가이샤 점안액
WO2002045748A1 (fr) * 2000-12-05 2002-06-13 Sankyo Company, Limited Compositions d'abaissement de la tension oculaire pour administration topique
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
ATE442849T1 (de) * 2004-03-18 2009-10-15 R Tech Ueno Ltd Wässrige zusammensetzung mit einem thiazol- derivat
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US8030349B2 (en) * 2005-08-02 2011-10-04 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable medicament
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
JP2007099647A (ja) * 2005-09-30 2007-04-19 Kobayashi Pharmaceut Co Ltd 粘膜適用組成物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
CN103768070A (zh) * 2006-03-13 2014-05-07 株式会社·R-技术上野 水性组合物
BRPI0709549A2 (pt) * 2006-03-17 2011-07-19 Johnson & Johnson Vision Care métodos para estabilizar composições instáveis oxidativamente
JP2010508306A (ja) * 2006-10-31 2010-03-18 アルコン リサーチ， リミテッド 眼障害を治療するためのｐａｉ−１結合調節因子
US20100120908A1 (en) * 2007-02-07 2010-05-13 Teika Pharmaceutical Co., Ltd Eye drop preparation comprising latanoprost
JP2009073788A (ja) * 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
JP5640207B2 (ja) * 2007-10-08 2014-12-17 セラオプティクスＴｈｅｒａｏｐｔｉｃｓ 水性眼用処方物
EP2254549B2 (en) * 2008-03-17 2019-05-29 Alcon Research, Ltd. Aqueous pharmaceutical compositions containing borate-polyol complexes
TWI544927B (zh) * 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
KR20140038404A (ko) * 2011-04-12 2014-03-28 가부시키가이샤 아루떼꾸 우에노 수성 안과용 조성물
US20130029919A1 (en) 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
PL2787968T3 (pl) 2011-12-07 2020-08-24 Allergan, Inc. Wydajne dostarczanie lipidów do ludzkiego filmu łzowego z użyciem wrażliwego na sól układu emulsyjnego
AU2015353701B2 (en) 2014-11-25 2021-03-25 Allergan, Inc. Stabilized omega-3 ophthalmic compositions
JP2022501438A (ja) * 2018-09-21 2022-01-06 アウフバウ・メディカル・イノベイションズ・リミテッドAufbau Medical Innovations Limited 緑内障用の組成物および方法
MX2021012399A (es) 2019-04-12 2021-12-10 Ecolab Usa Inc Limpiador antimicrobiano multiuso y métodos de fabricación y uso de este.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69100171T2 (de) * 1990-05-22 1993-10-28 Ueno Seiyaku Oyo Kenkyujo Kk Synergistische Kombination zur ophthalmischen Verwendung.
IE920397A1 (en) * 1991-02-07 1992-08-12 Allergan Inc 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f¹derivatives
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
EP0708646A1 (en) * 1994-05-06 1996-05-01 Alcon Laboratories, Inc. Use of vitamin e tocopheryl derivatives in ophthalmic compositions
US5631287A (en) † 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.

Also Published As

Publication number Publication date
NZ337322A (en) 2001-05-25
IL131041A0 (en) 2001-01-28
RU2197970C2 (ru) 2003-02-10
WO1998041208A1 (en) 1998-09-24
DE69820997T3 (de) 2011-10-06
EE9900410A (et) 2000-04-17
ES2214706T5 (es) 2011-02-02
BR9808016A (pt) 2000-03-08
AU7035398A (en) 1998-10-12
TW527187B (en) 2003-04-11
CZ299833B6 (cs) 2008-12-10
EP0969846B1 (en) 2004-01-07
CN1236775C (zh) 2006-01-18
SI0969846T2 (sl) 2010-12-31
CA2280089A1 (en) 1998-09-24
PL335168A1 (en) 2000-04-10
EP0969846B2 (en) 2010-08-25
BRPI9816218B1 (pt) 2016-04-12
DK0969846T4 (da) 2010-12-20
DK0969846T3 (da) 2004-04-13
JP2010043110A (ja) 2010-02-25
SI0969846T1 (en) 2004-06-30
NO994481D0 (no) 1999-09-16
AU738781B2 (en) 2001-09-27
DE69820997D1 (de) 2004-02-12
CN1249687A (zh) 2000-04-05
HUP0002194A2 (hu) 2000-12-28
EP0969846A1 (en) 2000-01-12
ZA982188B (en) 1998-09-17
EE04091B1 (et) 2003-08-15
PL197509B1 (pl) 2008-04-30
CY2526B1 (en) 2006-02-08
ES2214706T3 (es) 2004-09-16
JP4920124B2 (ja) 2012-04-18
ID22389A (id) 1999-10-07
ATE257385T1 (de) 2004-01-15
CL2009001870A1 (es) 2010-01-22
UA63938C2 (uk) 2004-02-16
CZ325799A3 (cs) 2000-01-12
HUP0002194A3 (en) 2012-08-28
NO327713B1 (no) 2009-09-14
AR002194A1 (es) 1998-01-07
MY122237A (en) 2006-04-29
CA2280089C (en) 2009-03-03
AR011192A1 (es) 2000-08-02
PT969846E (pt) 2004-05-31
HK1026841A1 (en) 2000-12-29
DE69820997T2 (de) 2004-12-09
JP2001515502A (ja) 2001-09-18
NO994481L (no) 1999-09-16
KR20000076330A (ko) 2000-12-26
HU228896B1 (en) 2013-06-28
KR100555818B1 (ko) 2006-03-03
CO4940427A1 (es) 2000-07-24

Similar Documents

Publication Publication Date Title
PE61899A1 (es) Composicion farmaceutica para reducir la hipertension ocular que comprende una prostaglandina y un agente de ajuste de tonicidad no ionico
KR890000098A (ko) 세포 및 조직 수복제
LU90837I2 (fr) Sonovue-hexaflorure et ses d-riv-s pharmaceutiquement acceptables
CO5011119A1 (es) Jarabe antihistaminico estabilizado
AR010288A1 (es) Composicion micobactericida concentrada acuosa; composicion desinfectante de superficies duras y metodo de desinfeccion de una superficie dura
RU94046143A (ru) Фармацевтическая композиция для лечения глаукомы
ATE273033T1 (de) Stabilisierte ophthalmische wasserstoffperoxidlösung
DK0572190T3 (da) Oftalmiske præparater indeholdende vitamin E eller en ester deraf som en aktiv ingrediens
RU2002103315A (ru) Офтальмическая композиция, содержащая кетотифен
RU2004129593A (ru) Офтальмическая композиция, содержащая аскомицин
KR960706472A (ko) 프로스타글란딘 유도체, 그의 염 및 그의 사용
SE8404930L (sv) Vattenhaltiga kompositioner, som innehaller stabiliserade enzymer
AR247804A1 (es) Composicion biocida sinergica y metodo para proteger con la misma composiciones industriales
AR017925A1 (es) Una formulacion acuosa para verter, topicamente aceptable, adaptada para su aplicacion externa localizada en un animal, su uso y un metodo para formularla
ES500581A0 (es) Un procedimiento para la preparacion de una composicion detergente blanqueadora, del tipo que genera peracidos organicos
DE69125360D1 (de) Alkylester von oxidiertem Glutathion
ATE85031T1 (de) Stabilisierung von wasserstoffperoxid.
ES2022448B3 (es) Composicion desinfectante para lentes de contacto blandas, que contienen una disolucion de peroxido de hidrogeno estabilizada.
SE8705064L (sv) Emulsion foer parenteral administrering
CO5601034A2 (es) Metodos para conservar soluciones oftalmicas y soluciones oftalmicas conservadas
ATE270869T1 (de) ZUSAMMENSETZUNG MIT KONTINUIERLICHER WÄSSERIGER PHASE, DIE L-2-OXOTHIAZOLIDIN- 4-CARBONSÄURE ENTHÄLTß.
FI965157A (fi) 2-((2,6-dikloorifenyyli)amiini)fenyyliasetoksietikkahapon uudet suolat orgaanisten emäksisten kationien kanssa
ES2106852T3 (es) Composicion oftalmica que contiene hemihidrato de timolol.
FI842966A (fi) Triazolo-pyrimidinderivat, foerfarande foer deras framstaellning samt deras terapeutiska anvaendning som hjaertmediciner.
GB1472084A (en) Composition and method for sterilizing contact lenses

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed